Lan_2017_Eur.J.Med.Chem_139_48

Reference

Title : Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease - Lan_2017_Eur.J.Med.Chem_139_48
Author(s) : Lan JS , Ding Y , Liu Y , Kang P , Hou JW , Zhang XY , Xie SS , Zhang T
Ref : Eur Journal of Medicinal Chemistry , 139 :48 , 2017
Abstract :

Combining N-benzyl pyridinium moiety and coumarin into in a single molecule, novel hybrids with ChE and MAO-B inhibitory activities were designed and synthesized. The biological screening results indicated that most of compounds displayed potent inhibitory activity for ChE and Abeta (1-42) self-aggregation, and clearly selective inhibition to MAO-B over MAO-A. Of these compounds, compound 7f was the most potent inhibitor for hMAO-B, and it was also a good and balanced inhibitor to ChEs and hMAO-B (0.0373 muM for eeAChE; 2.32 muM for eqBuChE; 1.57 muM for hMAO-B). Molecular modeling and kinetic studies revealed that compound 7f was a mixed-type inhibitor, which bond simultaneously to CAS and PAS of AChE, and it was also a competitive inhibitor, which occupied the active site of MAO-B. In addition, compound 7f with no toxicity on PC12 neuroblastoma cells, showed good ability to inhibit Abeta (1-42) self-aggregation and cross the BBB. Collectively, all these results suggested that compound 7f might be a promising multi-target lead candidate worthy of further pursuit.

PubMedSearch : Lan_2017_Eur.J.Med.Chem_139_48
PubMedID: 28797883

Related information

Citations formats

Lan JS, Ding Y, Liu Y, Kang P, Hou JW, Zhang XY, Xie SS, Zhang T (2017)
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease
Eur Journal of Medicinal Chemistry 139 :48

Lan JS, Ding Y, Liu Y, Kang P, Hou JW, Zhang XY, Xie SS, Zhang T (2017)
Eur Journal of Medicinal Chemistry 139 :48